According to Fig. 11A, the IPS score, IPS–PD1/PDL1/PDL2 blocker score, IPS-CTLA4 blocker score, and IPS-CTLA4 and PD1/PDL1/PDL2 blocker score were all significantly higher in the low-risk group, indicating that CESC patients with lower risk score might respond better to immunotherapy. The gene discussed is PDCD1; the disease is cervical squamous cell carcinoma.